Results 341 to 350 of about 3,169,653 (411)
Some of the next articles are maybe not open access.
Current Medicinal Chemistry, 2001
AMPA Receptor antagonists have received considerable attention in recent years. Within the class of excitatory amino acid receptor antagonists AMPA receptor antagonists have shown excellent neuroprotection in several models of cerebral ischemia and neuronal injury.
Sham Shridhar Nikam +1 more
openaire +2 more sources
AMPA Receptor antagonists have received considerable attention in recent years. Within the class of excitatory amino acid receptor antagonists AMPA receptor antagonists have shown excellent neuroprotection in several models of cerebral ischemia and neuronal injury.
Sham Shridhar Nikam +1 more
openaire +2 more sources
American Review of Respiratory Disease, 2015
Terfenadine (Seldane) is a new, highly potent H1 histamine receptor antagonist that in clinically effective doses is free of side effects. Because the low potency and specificity of many H1 receptor antagonists have made it difficult to define the ...
P. Rafferty, S. Holgate
semanticscholar +1 more source
Terfenadine (Seldane) is a new, highly potent H1 histamine receptor antagonist that in clinically effective doses is free of side effects. Because the low potency and specificity of many H1 receptor antagonists have made it difficult to define the ...
P. Rafferty, S. Holgate
semanticscholar +1 more source
Current Medicinal Chemistry-Cardiovascular & Hematological Agents, 2004
Type 1 receptors (AT1) for the peptide hormone angiotensin II play a crucial role in the cardiovascular homeostasis. In this regard, several selective, orally active non-peptide antagonists have been developed for the treatment of hypertension and congestive heart failure.
Ilse Verheijen +3 more
openaire +3 more sources
Type 1 receptors (AT1) for the peptide hormone angiotensin II play a crucial role in the cardiovascular homeostasis. In this regard, several selective, orally active non-peptide antagonists have been developed for the treatment of hypertension and congestive heart failure.
Ilse Verheijen +3 more
openaire +3 more sources
Prolactin Receptor Antagonists
Endocrine, 1998Most prolactin (PRL) in the circulation is produced by the pituitary. However, a wide variety of traditional target tissues of the hormone have also been shown to produce their own prolactin. The amount produced per cell is low, but may well be sufficient for autocrine/paracrine activity.
Chiaoyun Benson Kuo +2 more
openaire +3 more sources
Bradykinin receptors and their antagonists
European Journal of Pharmacology, 1998Bradykinin and related kinins act on two receptor types, named B1 and B2. Initially identified in classical bioassays, these receptors have been cloned and characterized in binding assays performed on plasma membranes of cells expressing the native or the transfected human kinin B1 or B2 receptor types.
Fernand Junior Gobeil +3 more
openaire +2 more sources
Neurokinin receptor antagonists
Expert Opinion on Investigational Drugs, 2000Studies on tachykinin peptides and the corresponding neurokinin receptors (NKr) have increased dramatically recently due to the discovery of selective, orally-active, metabolically stable and sometimes CNS penetrating NKr antagonists. After demonstrating the potential use for NKr antagonists in animal models, some compounds have recently progressed ...
Vincent Leroy +3 more
openaire +3 more sources
An antagonist decoy receptor and a death domain-containing receptor for TRAIL.
Science, 1997TRAIL, also called Apo2L, is a cytotoxic protein that induces apoptosis of many transformed cell lines but not of normal tissues, even though its death domain-containing receptor, DR4, is expressed on both cell types.
G. Pan +5 more
semanticscholar +1 more source
Vasopressin Receptor Antagonists
Current Hypertension Reports, 2015Arginine vasopressin (AVP) is the principal hormone involved in regulating the tonicity of body fluids. Less appreciated is the role that AVP plays in a variety of other physiologic functions including glucose metabolism, cardiovascular homeostasis, bone metabolism, and cognitive behavior.
openaire +2 more sources
Cholecystokinin receptor antagonists
American Journal of Physiology-Gastrointestinal and Liver Physiology, 1984Since 1979 three classes of cholecystokinin receptor antagonists have been described: 1) derivatives of cyclic nucleotides, 2) derivatives of amino acids, and 3) C-terminal fragments or partial sequences of cholecystokinin. These various antagonists share a number of common features, such as their specific, reversible, and competitive actions, but ...
R. T. Jensen, J. D. Gardner
openaire +3 more sources
Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.
Science, 1997Angiogenesis is thought to depend on a precise balance of positive and negative regulation. Angiopoietin-1 (Ang1) is an angiogenic factor that signals through the endothelial cell-specific Tie2 receptor tyrosine kinase.
C. MaisonpierrePeter +13 more
semanticscholar +1 more source